Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Key Vendor Analysis 2022Posted by sandeep gade on December 21st, 2022 Newly-released Anti-Vascular Endothelial Growth Factor Therapeutics Market industry analysis report by Persistence Market Research shows that global sales in 2021 were held at US$ 11.9 Bn. With a CAGR of 0.9%, the projected market growth during 2022-2032 is expected to be slightly higher than the historical growth. The Anti-Vascular Endothelial Growth Factor Therapeutics Market is accounted to give an absolute dollar opportunity growth of nearly US$ 1.1 Bn during 2022 – 2032. Eylea is expected to be the highest revenue-generating product type. Competitive Analysis The key companies operating in the Anti-Vascular Endothelial Growth Factors Therapeutics Market are F. Hoffmann-La Roche Ltd., Biogen, Pfizer, Inc., CoherusBioSciences, and Amgen, Inc. According to a WHO report published in 2021, over 196 million individuals worldwide are affected by AMD, with around 10.4 million instances resulting in moderate to severe vision impairment. As a result, the rise in ophthalmic disorders will necessitate the use of Anti-Vascular Endothelial Growth Factor Therapeutics in the future, which will serve as a catalyst for the Anti-Vascular Endothelial Growth Factor Therapeutics business. Some of the recent developments of Anti-Vascular Endothelial Growth Factor Therapeutics Market providers are as follows:
Similarly, the team at Persistence Market Research has tracked recent developments related to companies offering the Anti-Vascular Endothelial Growth Factor Therapeutics Market, which are available in the full report. Buy Full Report Now and Get Up to 20% Discount: https://www.persistencemarketresearch.com/samples/33243 Like it? Share it! More by this author |